105 related articles for article (PubMed ID: 21851370)
1. Mycophenolate mofetil for patients with autoimmune hepatitis and overlap syndromes.
García-Buey L; Moreno-Otero R
Aliment Pharmacol Ther; 2011 Sep; 34(6):682-4; author reply 684-5. PubMed ID: 21851370
[No Abstract] [Full Text] [Related]
2. The role of mycophenolate mofetil in the management of autoimmune hepatitis and overlap syndromes.
Baven-Pronk AM; Coenraad MJ; van Buuren HR; de Man RA; van Erpecum KJ; Lamers MM; Drenth JP; van den Berg AP; Beuers UH; den Ouden J; Koek GH; van Nieuwkerk CM; Bouma G; Brouwer JT; van Hoek B
Aliment Pharmacol Ther; 2011 Aug; 34(3):335-43. PubMed ID: 21668459
[TBL] [Abstract][Full Text] [Related]
3. Mycophenolate mofetil--a new treatment for autoimmune hepatitis?
Dhawan A; Mieli-Vergani G
J Hepatol; 2000 Sep; 33(3):480-1. PubMed ID: 11020006
[No Abstract] [Full Text] [Related]
4. Role of mycophenolate mofetil in the treatment of autoimmune hepatitis.
Schramm C; Lohse AW
J Hepatol; 2011 Sep; 55(3):510-511. PubMed ID: 21281682
[No Abstract] [Full Text] [Related]
5. Mycophenolate mofetil to the rescue in autoimmune hepatitis: a fresh sprout on the decision tree.
Czaja AJ
J Hepatol; 2009 Jul; 51(1):8-10. PubMed ID: 19446910
[No Abstract] [Full Text] [Related]
6. Histological changes after the use of mycophenolate mofetil in autoimmune hepatitis.
Brunt EM; Di Bisceglie AM
Hum Pathol; 2004 Apr; 35(4):509-12. PubMed ID: 15116334
[TBL] [Abstract][Full Text] [Related]
7. Use of mycophenolate in the treatment of autoimmune hepatitis.
Oo YH; Neuberger J
Liver Int; 2005 Aug; 25(4):687-91. PubMed ID: 15998416
[No Abstract] [Full Text] [Related]
8. Mycophenolate mofetil as a rescue therapy for autoimmune hepatitis patients who are not responsive to standard therapy.
Fallatah HI; Akbar HO
Expert Rev Gastroenterol Hepatol; 2011 Aug; 5(4):517-22. PubMed ID: 21780898
[TBL] [Abstract][Full Text] [Related]
9. [Mycophenolate mofetil--a new therapeutic agent for chronic autoimmune diseases].
Harboe E; Gøransson L; Wildhagen K; Omdal R
Tidsskr Nor Laegeforen; 2005 Jun; 125(12):1650-2. PubMed ID: 15976831
[TBL] [Abstract][Full Text] [Related]
10. Drug choices in autoimmune hepatitis: part B--Nonsteroids.
Czaja AJ
Expert Rev Gastroenterol Hepatol; 2012 Sep; 6(5):617-35. PubMed ID: 23061712
[TBL] [Abstract][Full Text] [Related]
11. Hepatitis: new hope for difficult cases of autoimmune hepatitis.
Halac U; Alvarez F
Nat Rev Gastroenterol Hepatol; 2009 Nov; 6(11):629-30. PubMed ID: 19881512
[No Abstract] [Full Text] [Related]
12. Iatrogenic immunodeficiency-associated lymphoproliferative disease of the Hodgkin lymphoma-like variant in a patient treated with mycophenolate mofetil for autoimmune hepatitis.
Adams B; Lazarchick J; Medina AM; Willner IR; Neville B; Murphy E; Stuart R; Costa LJ
Am J Hematol; 2010 Aug; 85(8):627-9. PubMed ID: 20658594
[No Abstract] [Full Text] [Related]
13. Seronegative autoimmune hepatitis presenting after diagnosis of coeliac disease: a case report.
Quail MA; Russell RK; Bellamy C; Mieli-Vergani G; Gillett PM
Eur J Gastroenterol Hepatol; 2009 May; 21(5):576-9. PubMed ID: 19318969
[TBL] [Abstract][Full Text] [Related]
14. Mycophenolate mofetil as an alternative treatment for autoimmune hepatitis.
Park SW; Um SH; Lee HA; Kim SH; Sim Y; Yim SY; Seo YS; Ryu HS
Clin Mol Hepatol; 2016 Jun; 22(2):281-5. PubMed ID: 27246353
[TBL] [Abstract][Full Text] [Related]
15. Transplant immunosuppressive agents in non-transplant chronic autoimmune hepatitis: the Canadian association for the study of liver (CASL) experience with mycophenolate mofetil and tacrolimus.
Chatur N; Ramji A; Bain VG; Ma MM; Marotta PJ; Ghent CN; Lilly LB; Heathcote EJ; Deschenes M; Lee SS; Steinbrecher UP; Yoshida EM
Liver Int; 2005 Aug; 25(4):723-7. PubMed ID: 15998421
[TBL] [Abstract][Full Text] [Related]
16. The use of immunosuppression in autoimmune hepatitis: A current literature review.
Cropley A; Weltman M
Clin Mol Hepatol; 2017 Mar; 23(1):22-26. PubMed ID: 28288505
[TBL] [Abstract][Full Text] [Related]
17. Mycophenolate mofetil in autoimmune hepatitis patients not responsive or intolerant to standard immunosuppressive therapy.
Inductivo-Yu I; Adams A; Gish RG; Wakil A; Bzowej NH; Frederick RT; Bonacini M
Clin Gastroenterol Hepatol; 2007 Jul; 5(7):799-802. PubMed ID: 17509945
[TBL] [Abstract][Full Text] [Related]
18. [Treatment of autoimmune hepatitis].
Múzes G
Orv Hetil; 2003 Jul; 144(30):1497-8. PubMed ID: 14569681
[No Abstract] [Full Text] [Related]
19. Beneficial response to mycophenolate mofetil by patients with autoimmune hepatitis who have failed standard therapy, is predicted by older age and lower immunoglobulin G and INR levels.
Nicoll AJ; Roberts SK; Lim R; Mitchell J; Weltman M; George J; Wigg A; Stuart K; Gow P; MacQuillan G; Tse E; Levy M; Sood S; Zekry A; Cheng W; Mitchell J; Skoien R; Sievert W; Strasser SI; McCaughan GW;
Aliment Pharmacol Ther; 2019 May; 49(10):1314-1322. PubMed ID: 30972807
[TBL] [Abstract][Full Text] [Related]
20. A single center review of the use of mycophenolate mofetil in the treatment of autoimmune hepatitis.
Hlivko JT; Shiffman ML; Stravitz RT; Luketic VA; Sanyal AJ; Fuchs M; Sterling RK
Clin Gastroenterol Hepatol; 2008 Sep; 6(9):1036-40. PubMed ID: 18586559
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
